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ABSTRACT 
Malaria is a disease that is caused by the Plasmodium genus. It is endemic in 
tropical areas. There are multiple drugs used for prophylaxis and treatment. 
However, the parasites have developed resistance towards most antimalarial 
pharmaceuticals. The pharmaceutical industry is generating new antimalarial 
pharmaceuticals, but the rate of new Plasmodium resistance is much faster.  
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Introduction  
 
 Malaria is a disease caused by the Plasmodium genus that is transmitted 
between humans by Anopheles mosquitoes. Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale, Plasmodium knowlesi, and Plasmodium malariae are the 
species of Plasmodium that invade humans. P. falciparum  and P. vivax  are the most 
common species that cause malaria in humans. P. falciparum is the most dangerous 
because of the multi-drug resistance on this strain of the disease.1 Malaria is both 
curable and preventable with medication therapy; however, a vaccine is not available.  
 According to the World Health Organization, in 2012, there were 
approximately 207 million cases of malaria resulting in 627,000 deaths.2 The 
overwhelming majority, 90%, of these cases happen in Africa.1 Most of the deaths 
occur in children. However, the rate of deaths in children has been reduced by 54% 
since 2000.2 The distribution of worldwide confirmed cases are shown in figure 1. 
Countries with the most confirmed cases are in sub-Saharan Africa and India. In the 
United States, most of the cases of malaria are due to international travelers that 
acquired the disease while visiting an endemic country.2 
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Figure 1 
 
Figure 1. This is a map from the World Health Organization showing the number of confirmed cases 
of malaria in 2010.   
 
 The major problem with antimalarials is the resistance that Plasmodium is 
developing towards these medications. The CDC defines antimalarial drug resistance 
as “the ability of a parasite strain to survive and/or multiply despite the administration 
and absorption of a drug given in doses equal to or higher than those usually 
recommended but within tolerance of the subject.”3 The Plasmodium genus has a 
complex genome that allows the parasite to switch between the two hosts. Resistance 
occurs through multiple spontaneous mutations that reduce the sensitivity of the 
strains to the antimalarial medications. When large populations of Plasmodium are 
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exposed to the drug, the rate of resistance increases greatly, because the parasites’ 
sensitivity to the medications are removed. However, the resistant strains will survive 
and multiply. Most of the mutations that cause resistance affect the erythrocyte stage 
of the Plasmodium, which affect the metabolism and action of the medication.4 This 
review will be focusing on the antimalarial pharmaceuticals available in the United 
States. 
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Chapter I: Background 
 
 Malaria has existed for over 4,000 years. The first description of the disease 
was in ancient Chinese medical writings, Nei Ching (The Canon of Medicine), around 
2700 BCE. By the fourth century BCE, the Greeks had documented the disease. 
Malaria had been the cause of a great decrease in population of the Greek city-states. 
Hippocrates documented the symptoms. The symptoms of malarial fever were 
documented in the Susruta, a Sanskrit medical treatise. The treatise first connected 
the bite of an insect to the cause of malarial fever.5 
 The Chinese discovered the first medication used for the treatment of malaria 
during the second century BCE. 52 Remedies, a medical treatise, documented of the 
use of the Qinghao plant (Artemisia annua) against malaria. However, it was not until 
340 CE when the antifever qualities of the plant were described in medical text. 
Artemisinin, the active ingredient of the Qinghao plant, was not isolated until 1971 by 
Chinese scientists. Artemisinin drug products are used today as antimalarial drugs in 
areas where there is resistance to chloroquine.5  
 The Spanish Jesuit missionaries documented the use of another medication in 
the early seventeenth century. The medication was found in the bark of a tree in Peru. 
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The bark had been recognized when it cured the Countess of Chinchon, the wife of 
the Viceroy of Peru, who had contracted the malarial fever. The tree was named 
Cinchona after the countess, and the bark was called Peruvian bark. Quinine, an 
antimalarial used today, is derived from Peruvian bark.5  
 On November 6th, 1880, in Constantine, Algeria, Charles Louis Alphonse 
Laveran, a French army surgeon, was treating a patient with malaria. When the 
French army surgeon examined the patient’s blood, he noticed a parasite in the blood. 
He believed there was only one parasite that caused the disease and he named it 
Oscillaria malariae.3 He was also able to discover part of the life cycle of malaria, 
because he observed the exflagellation of the male gametocyte in the blood. The 
motile gametocyte led him to believe the parasite was a protozoan. By not finding the 
parasite in the air, water, or soil of the marshland, Laveran was able to deduct that the 
parasite must live inside the mosquito.6  
 Six years after the parasite was discovered in the blood of a patient with 
malaria, Camillo Golgi determined there were multiple forms of the disease. He came 
to this conclusion by observing the fever trend of patients with malaria. He 
discovered that one form was characterized by having a fever every second day 
(tertian periodicity) and another form had a fever every third day (quartan 
periodicity). He was able to connect the fever with rupture of the red blood cell due to 
the release of mature merozoites that had accumulated in the cell.5  
 In 1890, Giovanni Batista Grassi and Raimondo Filetti named Plasmodium 
vivax and Plasmodium malariae, which were the first species of Plasmodium to be 
named. In 1897, William H. Welch renamed Oscillaria malariae, Plasmodium 
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falciparum, which is the cause of tertian periodicity fever. In 1922, John William 
Watson Stephens named and described Plasmodium ovale. In 1931, Robert Knowles 
and Biraj Mohan Das Gupta discovered Plasmodium knowlesi in a long-tailed 
macaque (a type of monkey). The first human case of malaria caused by P. knowlesi 
was documented in 1965.5 
 Ronald Ross was the first to prove Plasmodia were transferred from humans 
to mosquitoes in 1897. He observed the infected mosquitoes bit birds, which 
contracted malaria afterwards. In 1899, Grassi, Amico Bignami, and Guispeppe 
Bastianelli demonstrated that the sporogonic (sexual) cycle of the Plasmodium genus 
occurs in the Anopheles mosquito. They collected mosquitoes and let them bite 
malaria infected humans. Then, the investigators allowed the mosquitoes to bite 
healthy volunteers, whom consequently developed malaria. This led to the discovery 
of the transmission cycle of Malaria in humans.5 
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Chapter II: Life cycle of Malaria 
 
 The life cycle of malaria has two stages, a sexual stage and an asexual stage. 
The sexual stage occurs in an invertebrate definitive host. In malaria, the definitive 
host is a female Anopheles mosquito. The asexual stage occurs in an intermediate 
vertebrate host, which is the human.7 Figure 2 shows the life cycle of Malaria. 
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Figure 2 
 
Figure 2. This figure shows the life cycle of malaria in the Anopheles mosquito and the human host. 
The Life Cycle of Malaria- Biology [Internet]. Centers for Disease Control and Prevention. Available 
from: http://www.cdc.gov/malaria/about/biology/  
 
 The sexual stage, also known as the sporogonic cycle, begins when a female 
Anopheles mosquito feeds on a human infected with a Plasmodium. The red blood 
cells the mosquito ingests contain male and female Plasmodium gametocytes. In the 
mosquito, the male gametocytes, or microgametocyte, undergo exflagellation to form 
mature male gametes. At the same time the female gametocytes, or 
macrogametocytes, come together in the human red blood cell. The female 
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gametocytes shed the red blood cell becoming female gametes. The male gametes 
penetrate the female gametes forming a zygote.3,8 
 The zygote elongates into an ookinete, which infiltrates the stomach of the 
mosquito and attaches to the outer lining of the stomach. As the ookinetic enlarges it 
forms into an oocyst. The oocyst rapidly divides into sporoblasts, which do not have a 
defined nucleus. Once the sporoblasts develop a defined nucleus and break away 
from the stomach lining, they become sporozoites. The sporozoites migrate and 
invade the salivary gland of the mosquito. This normally takes 10 to 18 days after the 
intake of gametocytes. This is the end of the sexual stage of the life cycle of 
Plasmodium.3,8 
 The asexual stage begins when the sporozoites are transferred to a human host 
when the infected mosquito feeds. The asexual stage can be further divided into the 
exo-erythrocyte stage and the erythrocyte stage.3 
 The exo-erythrocyte stage occurs first, because the sporozoites travel to the 
liver of the human host and invade the hepatocytes.3 In the hepatocytes, the 
sporozoites mature into schizonts. After five to sixteen days, the schizonts rupture, 
they release merozoites, the haploid form of Plasmodium.8 Plasmodium vivax and 
Plasmodium ovale can remain in the hepatocyte in a dormant stage. The merozoites in 
the dormant phase are called hypnozoites.8 The merozoites exit the hepatocytes and 
enter the blood stream. Once the merozoites enter the blood stream, they penetrate the 
red blood cells of the human host. This begins the erythrocyte stage.9  
 In the erythrocyte stage, the merozoites join together to form ringed 
trophozoites in the red blood cells.10 The parasite consumes the hemoglobin through 
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its food vacuole. The hemoglobin is metabolized into heme, which is toxic to the 
parasite. So the parasite uses polymerase to detoxify heme into crystals of hemozoin 
pigment.11 The trophozoites mature into schizonts or into gametocytes.10 The schizont 
phase will rupture into merozoites and repeat the erythrocyte stage. The gametocytes 
are crescent-shaped and mature very slowly (around 10 days).10 The gametocytes are 
eventually ingested by the Anopheles mosquitoes starting the sexual stage.8 
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Chapter III: The Disease 
 
 Malaria can be categorized in two categories: uncomplicated or complicated 
(severe). If malaria is promptly diagnosed and treated, it is curable. The symptoms of 
malaria are associated with the erythrocyte stage, because of the waste and toxins 
caused by the destruction of the red blood cell by Plasmodium.12 
 Malaria is usually diagnosed by the presence of Plasmodium in the patient’s 
blood. Mild anemia, thrombocytopenia, increased bilirubin, and increased 
aminotransferases can also be helpful laboratory findings to diagnosis malaria.12 
 
Uncomplicated Malaria 
 Classical uncomplicated malaria has three stages: a cold stage, a hot stage, and 
a sweating stage. The cycle lasts between 6-10 hours. The cold stage consists of 
shivering. A patient in the hot stage suffers from fever, headaches, vomiting, and 
seizures (frequently in young children). The sweating stage consists of sweats and 
tiredness.12 
 Tertian and quartan periodicities are associated classical attacks. In tertian 
attacks the symptomatic stages occur every second day. These attacks are caused by 
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P. falciparum, P. vivax, and P. ovale. In quartan attacks, the symptomatic stages 
occur every third day. P. malariae  is the cause of quartan periodicity.12 
  Uncomplicated malaria can be misdiagnosed as influenza or the common 
cold. This occurs in countries where malaria is not common; therefore, the patient is 
not expected to have malaria. In endemic areas, malaria symptoms are recognized.12 
 
Severe Malaria 
 A patient has severe malaria when he or she suffers from organ failure or 
abnormalities in the blood or metabolism. Severe malaria is associated with cerebral 
malaria, severe anemia, hemoglobinuria, acute respiratory distress syndrome (ARDS), 
abnormal blood coagulation, low blood pressure, acute renal failure, hyperparasitemia 
(more than 5% of erythrocytes are infected with parasites), metabolic acidosis, and 
hypoglycemia. ARDS inhibits oxygen exchange through inflammation. Severe 
malaria requires urgent and aggressive treatment.12 
 
Incubation period 
 After an infected Anopheles mosquito, there is an incubation period that lasts 
from seven to thirty days. P. falciparum infections are associated with shorter 
incubation periods, while P. malariae is associated with longer incubation periods. 
During the incubation period, the patient will not have any symptoms. The incubation 
period can be pro-longed if the patient had taken antimalarial pharmaceuticals for 
prophylaxis. P. vivax and P. ovale infections both can have delayed onset of 
symptoms, since theses parasites can go into a dormant phase of the liver.12 
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Symptoms and Complications  
 The majority of complications and symptoms of malaria in the human host are 
associated with the erythrocyte stage of Plasmodium.8 The Plasmodium destroys the 
inside of the erythrocyte, which causes waste and toxins to build up in the infected 
red blood cell. When the merozoites cause the red blood cell to rupture, the toxins and 
wastes products enter the blood stream. Macrophages and other cytokine-producing 
cells are attracted to the waste products, such as hemozoin, and toxins, such as 
glucose phosphate isomerase. Resulting symptoms are fever and rigors.12 Moderate to 
severe shaking, chills, high fever, and profuse sweating occur in cycles. Headache, 
vomiting, and diarrhea may also occur.13  
 Malaria causes severe complications, and if left untreated usually result in 
death. These complications include cerebral malaria, breathing problems, organ 
failure, severe anemia, and low blood sugar. Cerebral malaria occurs when the 
infected erythrocytes occlude the small vessels that lead to the brain. This causes 
brain swelling or damage, which leads to coma. Breathing problems occur because of 
the accumulation of fluid in the lungs. Organ failure occurs in kidneys or liver 
malaria may cause spleen rupture. Severe anemia happens because the parasite 
destroys the red blood cells. Malaria and certain malarial drugs can cause low blood 
sugar.14 P. falciparum infections can cause cerebral malaria. Red blood cells with 
mature trophozoites stick to the vascular walls of small blood veins. This causes a 
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blockage of blood flow. Cerebral malaria occurs when the blockage is in a vein of the 
brain. This complication has about a 20% mortality rate.12, 15 
 
Sickle cell trait  
 In people possessing the sickle cell trait, a protective advantage against 
malaria is apparent. The sickle cell trait is one normal hemoglobin gene and one 
sickle hemoglobin gene. Sickle cell gene affects the beta chain of the hemoglobin. It 
is a single amino acid change of glutamate to valine at the 6th position. The 
erythrocytes affected by this mutation have a shorter life. Heterozygotes for the sickle 
genes show lower numbers of erythrocytes infected with Plasmodium and decrease 
incidence of severe complications of malaria, such as cerebral malaria and severe 
anemia. However, homozygotes do not have a protective advantage and are highly 
susceptible to the lethal effects of malaria. The frequencies of the sickle cell trait are 
high in malaria-endemic areas.16 
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Chapter IV: Blood Schizonticides 
 
Chloroquine 
General Drug Information 
 Chloroquine phosphate, an antimalarial drug, 4-aminoquinoline, was 
discovered in 1934. It is the most commonly used medication to treat acute, 
uncomplicated cases of malaria. Chloroquine can be administered to treat 
Plasmodium ovale, Plasmodium vivax, and Plasmodium falciparum. However, many 
strains of P. falciparum and P. vivax have developed resistance to chloroquine 
because of the over-use of chloroquine. This unfortunate consequence has resulted in 
chloroquine being less effective in countries where resistance has been 
demonstrated.5 
 Chloroquine is highly effective during blood stages of the life cycle of 
malaria; however, it is not effective against the exo-erythrocyte stage of the parasite 
nor when relapse occurs in certain cases of P. vivax and P. ovale. Chloroquine cannot 
prevent relapse because the dormant stage occurs in the hepaptocyte.17  
 For prophylaxis, chloroquine should be started one to two weeks before 
traveling to the malaria endemic area. While in the endemic country the drug should 
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be taken on the same day of the week once a week. After the traveler returns, he/she 
should continue taking chloroquine for four weeks. Chloroquine is given as a tablet of 
500mg with 300 mg of the base. It may be used in pregnant women and children. For 
children the dose is determined by weight, the standard is 5 mg/kg with a maximum 
of 300 mg of base. Side effects of chloroquine include gastrointestinal disturbance, 
headache, dizziness, blurred vision, insomnia, and pruritus.18 
 
Mechanism of Action 
 Chloroquine is classified as an aminoquinoline. The common mechanism of 
action of this class of pharmaceuticals is to inhibit the heme polymerase activity of 
the Plasmodium. The Plasmodium use heme polymerase to enzymatically convert 
heme, which is toxic to the parasite, to a hemazoin, which is nontoxic to the parasite. 
Therefore, the chloroquine activity of inhibiting the Plasmodium’s heme polymerase 
causes an increase of heme concentration in the red blood cell. It is expected that 
heme interrupts the biosynthesis of nucleic acids. Chloroquine binds to the heme that 
has accumulated to form the heme-chloroquine complex, which is highly toxic to 
Plasmodium. The heme-chloroquine complex interrupts the Plasmodium membrane. 
This causes lyses of the infected erythrocyte, which causes Plasmodium 
autodigestion.19  
 Chloroquine’s highest concentration is found in the Plasmodium’s food 
vacuole. The medication is able to enter the Plasmodium by simple diffusion. The 
alkaline nature of chloroquine is important in the food vacuole, because it raises the 
pH of the vacuole. This rise in pH causes denaturing of the pigment protein, which 
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results in clumping. The rise in pH inhibits digestion of the amino acids the parasite 
acquires from degrading the hemoglobin of the host’s red blood cells. Thus, 
chloroquine prevents Plasmodium from producing protein and creating energy that is 
needed for survival.19 
 
Resistance  
 P. falciparum and P. vivax have chloroquine-resistant strains. Chloroquine 
was very successful when it was first approved in 1934 for treatment of malaria. Its 
early effectiveness resulted in heavy use of the medication at high doses. There were 
other antimalarial pharmaceuticals, but none had the low cost and high effectiveness 
of chloroquine. This ultimately led to resistant strains. P. falciparum  and P. vivax are 
the most the common types of the parasite; therefore, they have the most exposure to 
chloroquine, which is why they have developed resistance.11 Figure 3 shows the areas 
of known chloroquine resistance in blue. 
 The first cases of resistance in P. falciparum were observed in Colombia and 
along the Thailand-Cambodia border in the late 1950s. In the1960s, resistance was 
noticed in parts of Southeast Asia, South America, and India. Cases of resistance in 
Africa were not identified until 1978, and those cases were initially noticed in Kenya 
and Tanzania, which are located on the eastern Africa sea border, near the equator. 
Within ten years of finding the resistant strains in Kenya and Tanzania, the P. 
falciparum chloroquine-resistant strain spread to the rest of Africa.11  
   The resistance found in P. falciparum has been found to correlate with a 
K76T (substitution for lysine with thyroxine at codon 76) point mutation of the gene 
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pfcrt (on chromosome 7). In fact, the K76T mutation is found in all resistant strains 
isolated and not in the sensitive strains isolated in the study performed by Djimde et 
al.4, 20 PfCRT, the gene product, is a transporter that is found in the food vacuole 
membrane that regulates drug efflux and pH regulation. It is believed that the P. 
falciparum resistance to chloroquine is due to the increased efflux of chlororquine out 
of the food vacuole caused by the mutation. Seven other point mutations have been 
associated with chloroquine resistant strains of Plasmodium: M74I, N75E, A220S, 
Q271E, N326S, I356T, and R371I.11 This mutation does not allow chloroquine to 
accumulate in the parasites food vacuole, thus, blocks the inhibition of the heme 
polymerase mechanism of the drug.21 The rate of expulsion of chloroquine in resistant 
strains is 30 to 40 times greater than strains that are sensitive to chloroquine.3 
 Another mutation pfmdr-1 and -2 also causes resistance to chloroquine. 
Pfmdr-1 is located on chromosome 5 and codes for P-glycoprotein homologne-1 
(Pgh-1). The mutation is a point mutation at codon 86 that switches aspartic acid for 
tyrosine. There are other mutations that have been shown to cause mutation, such as 
Phe 184, Cys 1034, Asp 1042, and Tyr 1246.4 
 Calcium channels blockers and other medications cause the efflux mechanism 
of the parasite can reverse the resistance of P. falciparum strains to chloroquine. The 
medications commonly used are verapamil and dilitazem.4 
 P. vivax resistance to chloroquine was not discovered until 1989 in Papua 
New Guinea. Resistance has spread to parts of South America and Southeast Asia.11  
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Figure 3 
 
 
 
Figure 3. This is a map of documented Plasmodium resistance to chloroquine. Data was complied 
using Centers of Disease Control and Guidelines for the Treatment of Malaria.22, 23 
 
 
Hydroxychloroquine 
  Hydroxychloroquine has the same structure as chloroquine with an additional 
hydroxyl group. The additional hydroxyl group does not cause any clinically 
significant pharmacokinetic differences between hydroxychloroquine and chloroquine 
according to a study by Tett, Cutler, Day and Brown.24 Therfore, hydroxychloroquine 
cannot be used in areas with known chloroquine resistance.25 
 For prophylaxis, hydroxychloroquine uses the same schedule as chloroquine. 
The dose is 400 mg tablet with 310 mg of the base. The maximum dose is one tablet. 
Pediatric patients should be given 5 m/kg.18 
 
20	  	  
 
Mefloquine 
General Drug Information  
 Mefloquine, an analog of quinine, is used to treat and prevent malaria. 
Mefloquine’s chemical structure is 2- piperidinyl-2,8- bis (trifuoromethyl)-4-
quinolinemethanol hydrochloride. Mefloquine is used for the prevention and 
treatment of P. falciparum and P. vivax. The medication is also effective against 
cholroquine-resistant strains of P. falciparum.26 It is also active against the 
gametocytes of P. vivax, P. ovale, and P. malariae. The destruction of gametocytes 
prevents further spread of the parasite to other mosquitoes and humans.27  
  For prophylaxis, a traveler should start taking mefloquine at least two weeks 
before travel. It is taken weekly on the same day of the week while in the malaria 
endemic country and four weeks after the traveler has returned home. For adults, 
mefloquine should be given as a 250 mg tablet with 228 mg of the base. It may be 
used for pediatric travelers. Children that weigh less than 9 kg should take 4.6 mg/kg. 
If they weigh between 9 and 19 kg they should take ¼ of the adult tablet. For patients 
weighing between 19 and 30 kg, they should be given ½ of the adult tablet. If they 
weigh between 30 and 35 kg, they should be given ¾ of the adult tablet. For children 
weighing more than 45 kg, they should be administered one full adult tablet. 
Common side effects include gastrointestinal disturbance, headache, insomnia, 
abnormal dreams, visual disturbances, depression anxiety, and dizziness.18 
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Mechanism of Action 
 Mefloquine acts on the erythrocyte stage Plasmodium; however, the 
medication is not effective against the exo-erythrocytes stages of Plasmodium. Thus, 
it is not effective against the dormant phase of P. ovale and P. vivax. The exact 
mechanism is unknown.25 In P. falciparum, melfloquine may cause swelling of the 
food vacuole. Mefloquine is suspected to bind with heme to generate toxic 
complexes, which then damage parasitic membranes and disrupt other cellular 
components.28  
 Mefloquine has also shown cross-resistance with halofantrine, which is an 
antimalarial drug used against erythrocyte stages. In patients that are receiving 
halofantrine and were previously treated with mefloquine, the Q-T interval duration 
has been increased to the point of causing cardiotoxicity. 24 
 
Resistance 
 Resistance to mefloquine is present within strains of P. falciparum. Resistant 
strains are found in Southeast Asia and the Amazon region of South America.22 
Mefloquine resistance has been associated with an increase in the number of copies of 
the pfmdr-1 gene.4 Figure 4 shows areas of known mefloquine resistance. 
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Figure 4 
 
 
Figure 4. This is a map of documented Plasmodium resistance to mefloquine. Data was complied using 
Centers of Disease Control and Guidelines for the Treatment of Malaria.22, 23 
 
 
Quinine sulfate 
General drug information 
 Quinine sulfate is an antimalarial agent that acts on the erythrocyte stages of 
Plasmodium.  The medication alkaloid derived from the bark of the cinchona tree. 
The use of quinine sulfate for the treatment of malaria has declined since the 
discovery of chloroquine, which is less toxic than quinine. Now, quinine is only used 
for malaria caused by multiple-drug resistant strains of Plasmodium.25 
  For treatment of malaria, quinine sulfate should be administered every eighth 
hour for seven days. The standard dose for pediatric and adult patients is 648 mg. 
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Most common side effects include diarrhea, nausea, gastrointestinal pain, and 
vomiting.29 
 
Mechanism of action 
 Quinine sulfate is a blood schizontocidal agent meaning it kills the schizont 
phase of erythrocyte stage.29 The precise mechanism of quinine sulfate is not 
known.30 Quinine inhibits nucleic acids, protein synthesis, and glycolysis of P. 
falciparum. It also inhibits the parasite’s mechanism of detoxifying heme by binding 
to the chemical used to convert hemozoin.30 
 
Resistance  
 Plasmodium resistance to quinine has been reported in areas of South 
America, Southeast Asia, and Bangladesh.29 The first report of the resistance was in 
Brazil about 100 years ago. The resistance developed in Southeast Asia in the 1980s 
because of the increased use of quinine.23 Like chloroquine and mefloquine, pfmdr-1 
mutations are associated with quinine resistance.4 The known pattern of quinine 
sulfate resistance is shown in figure 5.  
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Figure 5 
 
 
 
Figure 5. This is a map of documented Plasmodium resistance to quinine. Data was complied using 
Guidelines for the Treatment of Malaria.23 
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Chapter V: Tissue Schizonticides 
 
Pyrimethamine and sulfadoxine  
General drug information 
 Pyrimethamine and sulfadoxine are used synergistically to inhibit 
dihydrofolate reductase and dihydropteroate synthase. It works in the erythrocyte 
stage of P. falciparum and P. vivax. The combination product may be used in areas 
where there is chloroquine resistance.28 
 
Mechanism of action 
 The pharmaceutical drug class of antifolates work by blocking two of the key 
enzymes needed for the synthesis of folate sequentially and synergistically. 
Pyrimethamine inhibits dyhydrofolate reductase (DHFR). Sulfadoxine inhibits 
dyhydropteroate synthase (DHPS).4 
 
Resistance 
 Resistance is caused by gene mutation to both DHFR and DHPS. The 
resistance occurs at varying degrees.4 Resistance has been seen since the 1950s, about 
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ten years after the drug had been introduced as treatment for malaria. High-levels of 
resistance have been found in South-East Asia, southern China, and the Amazon 
region of South America. Lower levels of resistance are seen in Africa, Oceana, 
coastal areas of South America and southern Asia.31 
  Point mutations of dhps affect the efficacy of sulfadoxine of the combination 
product. The mutations are point mutations that occur on five codons: substitution of 
alanine or phenylalaine for serine at codon 436, glycine for alanine at codon 437, 
glutamic acid for lysine at codon 540, glycine for alanine at codon 581, and serine or 
threonine for alanine at codon 613. The mutation at 437 and 540 may occur together.4  
 Pyrimethamine resistance is associated with a point mutation on the dhfr gene. 
These mutations occur at codon 16 (substitution of valine for alanine), codon 51 
(isoleucine for aspargine), codon 59 (arginine for cysteine), codon 108 (asparginine 
for serine), and codon 164 (leucine for isoleucine and threonine). The main mutation 
for pyrimethamine resistance is the substitution of asparginine for serine.4 Figure 6 
shows the pattern of pyrimethamine and sulfadoxine resistance. 
Figure 6 
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Figure 6.This is a map of documented Plasmodium resistance to Pyrimethamine and sulfadoxine . Data 
was complied using Centers of Disease Control and Guidelines for the Treatment of Malaria.23 
 
 
Doxycycline  
General drug information 
 Doxycycline is a synthetic derivative of oxytetracycline used as a broad-
spectrum antibiotic. Doxycycline must be used in combination with other antimalarial 
pharmaceuticals to be effective.32 The effectiveness of doxycycline as an antimalarial 
pharmaceutical depends on the patient’s adherence to the medication.32 Even though 
doxycycline is an antibiotic, it can be used for prophylaxis of malaria for travelers 
who are visiting areas with known chloroquine and/or pyrimethamine-sulfadoxine 
resistant strains of P. falciparum. For prophylaxis, it is recommended that a person 
traveling to countries that have high malaria endemic rates start administration at least 
a day before traveling, then one dose for every day that the traveler is in the country, 
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and 28 days after the traveler has returned home. The regular dosing is 100 mg per 
day for adults.4 
 Doxycycline can be used in combination with quinine or other rapidly acting 
schizonticide. Doxycycline with quinine improve the efficacy of treatment in areas 
known chloroquine resistance strains of P. falciparum.32 
 
Mechanism of action 
 Doxycycline works in the erythrocyte stage. In studies, doxycycline destroys 
the schizont slowly. This medication shows no indication of sporocyte or gametocyte 
destruction. Doxycycline is metabolized in the liver.32 
 
Resistance  
 There have been cases of resistance to doxycyline. The cases occurred 
because of inadequate serum concentration levels of doxycycline, which is most 
likely due to non-adherence.32 
 
Atovaquone and proguanil (Malarone®) 
General drug Information 
 Atovaquone and proguanil hydrochloride are manufactured in combination as 
Malarone® for the prophylaxis and treatment of acute, uncomplicated malaria caused 
by P. falciparum. Malarone® has been observed to be effective in areas of 
chloroquine- and mefloquine-resistant strains.33 
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 For prophylaxis, atovaquone and proguanil hydrochloride therapy should be 
started one to two days before travel. It should be taken every day at the same time of 
day. The therapy should be taken while in the malaria endemic country and for seven 
days after leaving the endemic country. The adult tablets are 250 mg of atovaquone 
and 100 mg proguanil hydrochloride. It is not recommended for children less than 5 
kg and pregnant women. The pediatric tablet is 62.5 mg of atovaquone and 25 mg of 
proguanil hydrochloride. For children that weigh between 5 to 8 kg, should take ½ 
pediatric tablet as standard dose. Children weighing between 8 to 10 kg, take ¾ tablet 
daily. For children weighing between 10 to 20 kg, they should take one pediatric 
tablet.  Two pediatric tablets should be given to children weighing between 20 to 30 
kg. For children weighing between 30 to 40 kg, they should be administered 3 
pediatric tablets. One adult tablet should be given for those weigh more than 40 kg. 
Common side effects of atovaquone and proguanil hydrochloride are blurred vision, 
insomnia, dizziness, headache, gastrointestinal disturbance, and pruritus.18 
 
Mechanism of action 
 Malarone® interferes with the pathways of Plasmodia’s synthesis of nucleic 
acids. Atovaquone selectively inhibits the mitochondrial electron transport at the 
cytochrome bcl complex of the parasite, which stops ATP synthesis.4, 34 Proguanil 
hydrochloride disrupts the parasite’s deoxythymidylate synthesis by inhibiting the 
dihydrofolate reductase inhibitor.34 
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Resistance  
 Resistance to atovaquone is caused by a single-point mutation in the 
cytochrome-b gene (cytB).4 However, there is no known resistance to proguanil, 
which is thought to be the more important component of this combination.23 
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Chapter VI: Hypnozoitocides 
 
Primaquine 
General drug information 
 Primaquine phoshate, 8-[(4-amino-1-methylbutyl)amino]-6-methoxyquinoline 
phosphate, is an antimalarial pharmaceutical that inhibits the relapse of P. vivax. It 
was the first and only pharmaceutical discovered that would terminate the exo-
erythrocyte stage of P. vivax and P. ovale. Primaquine is typically only used for 
treatment. This mediation is recommended as a radical cure and prevention of relapse 
of malaria caused by P. vivax, and for use in areas of endemic malaria caused by P. 
vivax. Primaquine is recommended after the termination of chloroquine administered 
as suppressive therapy.35 
 If a case of P. vivax malaria occurs, it is recommended to take primaquine 
along with chloroquine. Chloroquine eliminates the erythrocyte stage of the parasite 
and terminates the paroxysm. To destroy the parasite in the exo-erythrocyte stage, 
primaquine should be administered concurrently with chloroquine.35 
 For prophylaxis, primquine therapy should be started one or two days before 
traveling to malarious areas. The medication should be taken at the same time 
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everyday while in the endemic country and for seven days afterwards. The adult dose 
is 30 mg of base in 52.6 mg of salt. Pediatrics should take 0.5mg/kg of base with a 
maximum dose of 30 mg of base. The most common side effect is gastrointestinal 
upset.18  
 
Mechanism of Action 
 The exact mechanism of action of primaquine is not known. It is suspected 
that primaquine may act by producing a reactive oxygen species or by disrupting the 
electron transport of Plasmodium. Primaquine may change the DNA of the parasite.36 
 However, the basic effects of primaquine towards Plasmodium are known. 
Primaquine inhibits the parasite from converting heme to a non-toxic agent by 
interfering with the mitochondria. Primaquine’s interference with the parasite’s 
mitochondrion inhibits the production of ATP, which the parasite needs to generate 
the chemicals to detoxify the heme. Thus, the parasite is eliminated.36 
 In the exo- erythrocyte stage, primaquine kills the intrahepatic form of P. 
vivax and P. ovale. This mechanism of primaquine prevents the relapse of malaria 
that is associated with P. vivax and P. ovale. Also, primaquine eliminates all forms of 
Plasmodia gametocytes preventing the spread of malaria by the Anopheles 
mosquito.36 
 
Resistance  
 The main concern with resistance is that primaquine is the only 
pharmaceutical that terminates the hypnozoite form of P. vivax and P. ovale and 
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prevents relapse. The resistance to primaquine occurs in the elimination of the P. 
vivax in the exo-erythrocyte stage. The resistance is primarily due to lower dosing of 
primaquine, a shorter duration of treatment, and patient non-compliance.37 
 The resistance due to a lower dose than recommended primarily happens 
because of the adverse effects of primaquine at higher doses and/or the miscalculation 
of dosage for an individual patient.37 The normal dose given is 15 mg of primaquine 
for 14 days to fully eradicate the exo-erythrocyte stage of P. vivax.35 Primaquine is 
more effective at higher doses than recommended 15 mg. However, the adverse 
effects of primaquine are dose related. The dosing of primaquine is based on the 
patient’s weight. If too low of a dosage is calculated, it will be ineffective. If the 
duration of treatment with primaquine is shorter than recommended, primaquine also 
becomes ineffective and allows the parasite to develop resistant strategies to the 
drug.37 
 Non-compliance by the patient is another issue that causes primaquine 
resistance. With the recommended 14-day treatment of primaquine, the patient may 
stop taking the medication after the illness symptoms resolve, especially if the patient 
suffers from any adverse effects from the medication. This would, in turn, allow P. 
vivax the opportunity to develop a resistance mechanism against the drug.37 
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Chapter VII: Artemisinin 
 
Arthemether and lumenfantrine 
General Information 
 The United States Food and Drug Administration approved the first 
artemisinin-based combination treatment (ACT), Coartem® (arthemether and 
lumenfantrine).38 Coartem® is indicated for the treatment of acute, uncomplicated 
malaria infection due to Plasmodium falciparum in patients weighing more than 5 kg. 
It is not indicated for complicated malaria or the prophylaxis.39 It has shown high 
effectiveness in areas of known multi-antimalarial resistance to treat malaria.38 Each 
Coartem® tablet consists of 20 mg of arthemether and 120 mg of lumenfantrine. It is a 
3-day regimen with doses 2 times a day. One dose consists of 4 tablets if the patient 
weighs more than 35 kg. For patients that weigh between 25 kg and 35 kg the dose 
should be 3 tablets. For patients that weigh between 15 kg and 25 kg the dose should 
be 2 tablets. For patients that weigh between 5 kg and 15 kg, the dose should be 1 
tablet.39 
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Mechanism of Action 
 Together, arthemether and lumenfantrine inhibit nucleic acid and protein 
synthesis. Arthemether is metabolized predominantly by CYP450 3A4 and CYP450 
3A5 into dihydroartemisinin, which is an active metabolite. Lumefantrine inhibits the 
formation of Beta-hematin by forming a complex with hemin.40 
 
Resistance 
 The Center of Disease Control did not adopt arthremether and lumenfantrine 
as the first-line drug for treatment of uncomplicated malaria until 2004. Because this 
drug is relatively new, there are no confirmed regions of Plasmodium resistance.41 
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Chapter VIII: Future resistance 
 
 Malaria will continue to be a problem worldwide. Plasmodium will continue 
to develop resistance against antimalarial pharmaceuticals. The parasite develops 
resistance much faster than the rate of new pharmaceuticals is being developed. It is 
thought that the only way to prevent malaria and cases of resistance is find another 
way to treat the disease besides medications. The industry is working on developing 
vaccines, but the Plasmodium genus has so many different sequences it has proven 
very difficult to do.4 
 Most pharmaceuticals that are being developed are artemesinin-combined 
treatment, which are pharmaceuticals that have a form of artemesinin and another 
drug. It is hoped that these combination drugs will slow the rapid rate of Plasmodium 
resistance.42 The World Health Organization (WHO) believes ACTs are the key, 
because the artemisinin component is highly active with only a short regimen. They 
rapidly clear the erythrocyte stage, which leads to the reduction of gametocytes that 
cause transmission. The second component has a longer acting effect. The WHO 
recommends five ACTs as first-line treatment against acute uncomplicated malaria. 
However, Coartem® is the only ACT available in the United States.43 
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 Resistance has also been associated with low drug concentrations. The low 
drug concentrations occur because of poor adherence taking the medication, sub-
standard drugs, or unusual pharamcokinetics. The patient may be non-adherent to the 
medication because of the common side effects associated with the antimalarial 
pharmaceuticals. One of the common adverse effects of the medication and symptom 
of malaria is vomiting, which can also lower the drug concentration in the patient. 
The pharmacokinetics of the pharmaceuticals can be altered by the function of 
enzymes that metabolize the drug. For example, artemether, which is a component of 
Coartem®, is metabolized into an active metabolite by CYP450 3A4 and 3A5. If the 
patient is a poor metabolizer of one of these enzymes, the concentration of the active 
metabolite will be lowered. This lower concentration allows the parasite to develop 
resistance.44  
 The CDC defines sub-standard antimalarial pharmaceuticals as “having no 
active ingredients, they may have less than the required amount of active ingredient, 
or they may contain ingredients which are not what is described on the package 
label.” In poor countries, counterfeit drugs are often found with lower concentration 
of the active ingredients. The lower concentration of active ingredients allows the 
parasite to develop resistance. These countries tend to have very little or no 
pharmaceutical regulation or enforcement.45 
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Conclusion 
 
 Malaria has been around almost 4,000 years. The Plasmodium genus is 
responsible for the disease. P. falciparum  and P. vivax are the most common species 
that cause the disease. The parasite needs two hosts to complete the life cycle, the 
Anopheles mosquito and humans.   
 Symptoms can occur in a tertian or quartan cycle. Symptoms occur with the 
erythrocyte stage of the plasmodium. The most severe complication is severe cerebral 
malaria caused by P. falciparum.  
 The sickle cell trait enhances a person’s protection against malaria. The trait 
occurs at a higher frequency in areas that are known as malaria endemic.  
 Plasmodium have developed resistance to chloroquine because the over-use at 
high doses of chloroquine. The Plasmodia develop resistance through single amino 
acids mutations. Quinine sulfate and mefloquine have also caused pmfdr mutations in 
the Plasmodium genome that have resulted in the resistance. Malarone® resistance is 
due to cytochrome-b mutation that effects the atovaquone component’s action. There 
are mutations that cause resistance to both components of pyrimehtamine and 
sulfadoxine. Primaquine resistance has been attributed to mutations caused by poor 
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adherence by patients to the medication or to a miscalculation of dosage that should 
be given to patient.  
  Today, Plasmodium develops resistance to the antimalarial medications faster 
than the pharmaceutical industry can develop antimalarial medication. The main 
cause of resistance is lower concentrations of the active ingredient of the antimalarial 
pharmaceuticals caused by lack of compliance, vomiting, sub-standard drugs, and/or 
pharmacokinetics. Resistance will continue to be a problem associated with 
antimalarial medications. The pharmaceutical industry must develop another way 
besides medications to prevent malaria, otherwise resistance will continue. 
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